Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept Auto-injector vs Manual Injection PK Study
NCT02799498Phase 1Completed
- Sponsor
- Amgen
- Start
- Oct 2003
- Primary completion
- Jan 2004
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 1, randomised, open-label trial of etanercept in rheumatoid arthritis (RA), plaque psoriasis, psoriatic arthritis (PsA) and 2 more, sponsored by Amgen. Primary endpoint: Area Under the Concentration-Time Curve from Time Zero to Time t at 28 days. Started Oct 2003; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)plaque psoriasispsoriatic arthritis (PsA)ankylosing spondylitis (AS)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT02799498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799498.